Show simple item record

dc.contributor.authorBarnieh, Francis M.
dc.contributor.authorLoadman, Paul M.
dc.contributor.authorFalconer, Robert A.
dc.date.accessioned2021-02-15T11:08:21Z
dc.date.accessioned2021-02-17T09:01:24Z
dc.date.available2021-02-15T11:08:21Z
dc.date.available2021-02-17T09:01:24Z
dc.date.issued2021-02
dc.identifier.citationBarnieh FM, Loadman PM and Falconer RA (2021) Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Research in Pharmacology and Drug Discovery. 2: 100017.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18345
dc.descriptionYesen_US
dc.description.abstractThe DNA damage response (DDR) is now known to play an important role in both cancer development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia mutated and Rad3-related) kinase, a major regulator of DDR, has demonstrated significant therapeutic potential in cancer treatment, with ATR inhibitors having shown anti-tumour activity not just monotherapies, but also in potentiating the effects of conventional chemotherapy, radiotherapy, and immunotherapy. This review focuses on the biology of ATR, its functional role in cancer development and treatment, and the rationale behind inhibition of this target as a therapeutic approach, including evaluation of the progress and current status of development of potent and specific ATR inhibitors that have emerged in recent decades. The current applications of these inhibitors both in preclinical and clinical studies either as single agents or in combinations with chemotherapy, radiotherapy and immunotherapy are also extensively discussed. This review concludes with some insights into the various concerns raised or observed with ATR inhibition in both the preclinical and clinical settings, with some suggested solutions.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.crphar.2021.100017en_US
dc.rights(c) 2021 Crown Copyright. This is an Open Access article distributed under the Creative Commons CC-BY-NC license (http://creativecommons.org/licenses/by-nc-nd/4.0/)en_US
dc.subjectDDRen_US
dc.subjectATRen_US
dc.subjectATMen_US
dc.subjectATR inhibitorsen_US
dc.subjectChemo- and radiosensitisersen_US
dc.titleProgress towards a clinically-successful ATR inhibitor for cancer therapyen_US
dc.status.refereedYesen_US
dc.date.Accepted2021-01-24
dc.date.application2021-02-05
dc.typeArticleen_US
dc.type.versionPublished versionen_US
dc.date.updated2021-02-15T11:08:22Z
refterms.dateFOA2021-02-18T08:36:17Z
dc.openaccess.statusGreenen_US


Item file(s)

Thumbnail
Name:
Barniehetal_ATRinhibitors_Curr ...
Size:
1.002Mb
Format:
PDF
Description:
barnieh_et_al_2021

This item appears in the following Collection(s)

Show simple item record